Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Blackstone goes into Thursday's Q3 print having just suffered its sharpest single-day drop in recent weeks, with the stock down 4.2% on Tuesday to $109.98, extending a 14% one-month decline that has reset the setup heading into the release.
The analyst response to the move has been swift and consistent. UBS cut its price target yesterday to $116 from $122, keeping a Neutral rating. That follows TD Cowen's Monday trim from $154 to $144 (Buy retained) and Barclays' cut last week from $128 to $124. The direction of travel is uniform: targets coming down across the ratings spectrum, from the bulls trimming ambition to the neutrals lowering their floor. Wells Fargo initiated at Equal-Weight with a $122 target earlier this month. The consensus mean now sits at $140.55, implying roughly 28% above Tuesday's close. That gap is wide enough to reflect genuine disagreement about when the earnings inflection arrives, not just how large it will be. The bull case rests on $1.35 trillion in total AUM, accelerating base management fees into 2027, and easing BCRED redemptions. The bear case points to a second consecutive quarter where management fees missed, a soft realization backdrop flagged by management for Q3, and dry powder still sitting idle, earning nothing until deployed.
Options positioning captures the mood precisely. The put/call ratio has ticked up to 1.71, above its 20-day average of 1.66, and sits near the upper end of the past year's range (52-week high 1.87, low 1.22). The ratio has been elevated since late September, when it jumped from a mid-1.40s base to the current 1.70 band, a shift that coincided with the stock's steepest leg down. The z-score is a modest 0.74, so this is not a panic reading, but the sustained elevation of put demand over a three-week stretch is a sign that options traders are paying for protection rather than chasing upside into the print. Short interest, by contrast, tells a less alarmed story. SI rose 17.6% on the week to 2.9% of the free float, reversing a multi-week decline that had brought it down from a September peak near the same level. That brings SI back to where it was in early September, and the absolute level remains low. The borrow market is easy: cost to borrow is 0.43%, up 8% on the week but trivially cheap in any absolute sense, and availability at 2,658% means there is no competition for shares among short sellers. The week's SI jump looks more like tactical positioning ahead of a known catalyst than a structural bearish buildup.
The stock's one-day reaction at the last comparable print was a 5.8% gain. The prior quarterly print produced a 4.2% loss on the day. The five-day move after the most recent result was a further 4.3% gain, suggesting that when Blackstone clears the bar, the relief trade has had legs. The bar this quarter is set by the fee-related earnings line: whether management fees stabilise sequentially and whether the realization pipeline has unclogged since the soft Q2. Wikipedia attention for the stock has spiked, with a z-score of 1.92 against its own 90-day history, placing BX in elevated retail attention territory heading into the release.
Among close peers, the pressure has been broadly felt but unevenly distributed. KKR fell 4.8% on Tuesday and is down 3.9% on the week. TPG dropped 4.9% on the day. ARES and CG were off 2.1% and 2.6% respectively. OWL bucked the group, up 2.4% on the week, suggesting some rotation toward the simpler, credit-oriented fee structures. BX, with its real estate and realization exposure, is taking the heaviest discount in the large-cap alternatives group right now.
Thursday's print is therefore less about whether Blackstone's long-run AUM compounding story is intact and more about whether Q3 management fees show any sequential life, and whether management's realization commentary is concrete enough to give the bulls something to price.
See the live data behind this article on ORTEX.
Open BX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.